[CAS NO. 6080-58-6] Lithium citrate tetrahydrate
PRODUCTS SPECIFICATIONS [6080-58-6]
DESCRIPTION [6080-58-6]
Overview
| MDL | MFCD00150030 |
|---|---|
| Molecular Weight | 281.98 |
| Molecular Formula | C6H13Li3O11 |
| SMILES | O=C(CC(C(O[Li])=O)(O)CC(O[Li])=O)O[Li].O.O.O.O |
2 Publications Citing Use of MCE
Summary
Lithium citrate (Litarex) tetrahydrate is the major active ingredient of Garcinia cambogia. Lithium citrate tetrahydrate competitively inhibits ATP citrate lyase with weight loss benefits. Lithium citrate tetrahydrate effective inhibits stones formation and also inhibits HIF , and has antioxidation, anti-inflammation and anti-tumor effects [1] [2] [3] [4] .
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Lithium citrate tetrahydrate shows an HIF inhibitory effect compared with the control group in ARPE19 cells and 661W cells. Lithium citrate tetrahydrate can downregulate Hif1a and the downstream genes in ARPE19 cells and 661W cells. Lithium citrate tetrahydrate suppresses HIF-1α protein expression increased by CoCl
2
administration in ARPE19 cells and 661W cells
[2]
.
In chicken hepatocytes, Lithium citrate tetrahydrate decreases the accumulation of lipid droplets and accelerated energy metabolism. Lithium citrate tetrahydrate protects the cells from ER stress by increasing the antioxidant status and mitochondrial functions
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Lithium citrate (100-200 mg/kg) tetrahydrate treatment could reduce markers of renal impairment (Blood Urea Nitrogen and serum creatinine). There is significantly less calcium oxalate crystal deposition in mice (male C57BL/6J mice) treated with Lithium citrate tetrahydrate. Lithium citrate tetrahydrate attenuates the oxidative stress induced by calcium oxalate crystallization. Lithium citrate tetrahydrate has inhibitory effects on calcium oxalate-induced inflammatory cytokines, such as MCP-1, IL-1 β, and IL-6. In addition, Lithium citrate tetrahydrate alleviates tubular injury and apoptosis caused by calcium oxalate crystals
[1]
.
The administration of Lithium citrate tetrahydrate can suppress body weight gain and fat accumulation in animals
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03631446 | Ferring Pharmaceuticals |
Bowel Cleansing
|
August 29, 2017 | |
| NCT02386449 | Ferring Pharmaceuticals |
Bowel Preparation
|
February 2015 | Phase 4 |
| NCT02255812 | University Hospital, Basel, Switzerland |
Exploratory Behavior
|
March 2013 | Not Applicable |
| NCT03593252 | McMaster University|McMaster Pediatric Surgery Rresearch Collaborative (MPSRC) |
Colostomy|Hirschsprung Disease - Pull Through|Necrotizing Enterocolitis|Inflammatory Bowel Diseases|Meconium Ileus|Bowel Obstruction|Elective Surgery
|
January 1, 2022 | Not Applicable |
| NCT02294838 | British Columbia Cancer Agency |
Parotid Neoplasms
|
December 2014 | Not Applicable |
| NCT01711437 | Azienda Policlinico Umberto I |
Colonoscopy
|
January 2011 | Phase 4 |
| NCT04033250 | Rambam Health Care Campus |
Inadequate Preparation for Colonoscopy; Personalized Colonoscopy Preparation
|
September 2019 | Not Applicable |
| NCT03851393 | Hull University Teaching Hospitals NHS Trust |
Cough
|
August 2014 | Not Applicable |
| NCT01754779 | University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Calcium Phosphate Kidney Stones
|
July 2012 | Phase 2 |
| NCT02039999 | Hull University Teaching Hospitals NHS Trust |
Cough
|
February 2015 | Not Applicable |
| NCT02714075 | Swiss Federal Institute of Technology|University for Development Studies, Tamale, Ghana |
Iron Deficiency and+or Anemia
|
April 2016 | Not Applicable |
| NCT02492126 | Mayo Clinic|University of Manchester |
Cough
|
January 2016 | |
| NCT04700475 | Nada Yousef|Cairo University |
Head and Neck Cancer
|
September 4, 2020 | Not Applicable |
| NCT01481714 | Infante, Javier Molina, M.D. |
Bowel Cleansing|Colonoscopy
|
November 2011 | Phase 4 |
| NCT03639727 | Kuopio University Hospital|University of Helsinki |
Chronic Cough
|
September 1, 2018 | Not Applicable |
| NCT01984008 | Universal Integrated Corp. |
Bowel Preparation Before Colonoscopy
|
October 23, 2013 | Phase 3 |
| NCT03999203 | Queen´s University, Belfast|King´s College London |
Asthma|Cough
|
October 4, 2017 | |
| NCT05592327 | Universitat Internacional de Catalunya|Klockner Implant System |
Peri-Implantitis|Implant Infection|Microbial Disease
|
November 3, 2022 | Not Applicable |
| NCT03578900 | Grupo de Investigação em Bioquímica e Biologia Oral|University of Lisbon|Portuguese Institute of Rheumatology|Dentaid SL |
Xerostomia|Hyposalivation|Quality of Life|Sjogren´s Syndrome
|
January 1, 2013 | Phase 4 |
| NCT01421160 | Texas Tech University Health Sciences Center, El Paso |
Arthritis
|
July 2011 | Phase 1 |
| NCT03017235 | Ferring Pharmaceuticals |
Bowel Preparation
|
February 20, 2017 | Phase 3 |
| NCT02359942 | Seoul National University Bundang Hospital |
Helicobacter Pylori Infection
|
March 1, 2015 | Not Applicable |
| NCT03769402 | Ain Shams University |
Intrabony Periodontal Defect
|
January 1, 2016 | Phase 4 |
| NCT03095378 | University of Sao Paulo |
Gingival Recession
|
March 10, 2014 | Not Applicable |
| NCT04741620 | Hospital de Mataró |
Oropharyngeal Dysphagia|Dysphagia|Swallowing Disorder
|
January 17, 2019 | Not Applicable |
| NCT04161599 | Hospital Universitari Vall d´Hebron Research Institute |
Wounds and Injuries|Surgery--Complications
|
March 1, 2022 | Phase 4 |
Appearance
Solid
Source
Aspergillus niger
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : ≥ 100 mg/mL ( 354.64 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5464 mL | 17.7318 mL | 35.4635 mL |
| 5 mM | 0.7093 mL | 3.5464 mL | 7.0927 mL |
| 10 mM | 0.3546 mL | 1.7732 mL | 3.5464 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (177.32 mM); Clear solution; Need ultrasonic
References
- [1] Liu X, et al. Hydroxycitric acid inhibits renal calcium oxalate deposition by reducing oxidative stress and inflammation. Curr Mol Med. 2020 Jan 3.
- [2] Ibuki M, et al. Therapeutic Effect of Garcinia cambogia Extract and Hydroxycitric Acid Inhibiting Hypoxia-Inducible Factor in a Murine Model of Age-Related Macular Degeneration. Int J Mol Sci. 2019 Oct 11;20(20). pii: E5049.
- [3] Han S, et al. Hydroxycitric Acid Tripotassium Inhibits Calcium Oxalate Crystal Formation in the Drosophila Melanogaster Model of Hyperoxaluria. Med Sci Monit. 2019 May 17;25:3662-3667.
- [4] Heymsfield SB, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998 Nov 11;280(18):1596-600.
Synonyms
